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APCs = antigen-presenting cells; IFN = interferon; IL = interleukin; LAP = latency-associated peptide; RA = rheumatoid arthritis; SLE = systemic
lupus erythematosus; TβR = TGF-β receptor; TCR = T-cell receptor; TGF = transforming growth factor; Th = T helper cell; Treg = regulatory T
cell(s); TSP = thrombospondin.
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Abstract
Naturally occurring CD4+CD25+ regulatory T cells mediate immune
suppression to limit immunopathogenesis associated with chronic
inflammation, persistent infections and autoimmune diseases. Their
mode of suppression is contact-dependent, antigen-nonspecific and
involves a nonredundant contribution from the cytokine transforming
growth factor (TGF)-β. Not only can TGF-β mediate cell–cell
suppression between the regulatory T cells and CD4+CD25– or
CD8+ T cells, but new evidence also reveals its role in the
conversion of CD4+CD25– T cells, together with TCR antigen
stimulation, into the regulatory phenotype. Elemental to this
conversion process is induction of expression of the forkhead
transcription factor, Foxp3. This context-dependent coercion of naive
CD4+ T cells into a powerful subset of regulatory cells provides a
window into potential manipulation of these cells to orchestrate
therapeutic intervention in diseases characterized by inadequate
suppression, as well as a promising means of controlling pathologic
situations in which excessive suppression dominates.
Introduction
Autoimmune diseases are characterized by a loss of
regulation of T cell growth and activation, with resultant
overexuberant inflammation and tissue destruction.
Although T cell responses to foreign antigens are essential
to our protection from a plethora of potentially pathogenic
agents and microbes, T cell responses to self antigens
can be overtly deleterious. As the signaling pathways
associated with T cell activation continue to be
illuminated, there is also an emerging excitement about
naturally occurring opposing forces that can exert control
over antigen-activated T cells to prevent reactivity to self.
Suppressor T cells, implicated in this regulatory process
decades ago, fell into ill repute but have recently re-
emerged not only as a real population but as a population
crucial to immune homeostasis, maintenance of tolerance,
and prevention of the onset of autoimmune disease. Their
existence is no longer in question, but true to their history
these cells, their origin, generation, and mechanisms of
action have generated considerable controversy.
Recognition of the potential impact of these cells in
clinical cellular therapy has driven a rapid expansion of the
field in order to understand and manipulate the regulatory
T cell population to devise strategies to control auto-
immunity, transplantation tolerance, tumor immunity,
allergy and infectious diseases, particularly HIV.
One of the most intensely studied of the heterogeneous
family of regulatory T cells is a population of CD4+ T cells
constitutively expressing CD25 (IL-2Rα), found in thymus
and in peripheral lymphoid organs, and comprising 5 to
10% of the total CD4+ T cells in mice and humans [1–5].
On the basis of their unique functional properties, this
small but powerful population of T cells has been dubbed
CD4+CD25+ regulatory T cells (Treg). In contrast to
CD4+CD25– T cells, freshly isolated CD4+CD25+ Treg
are anergic to TCR stimulation in vitro. However, once
activated, these Treg are robust suppressors and can
mediate the inhibition of CD4+CD25– responder T cells
by means of a cell-contact-dependent mechanism
involving transforming growth factor (TGF)-β [6–9]
(Fig. 1). Although the role of TGF-β has not yet been
universally accepted [10,11], the preponderance of
evidence has solidified a contribution from TGF-β in the
regulatory process [6–8,12–15].
The essentiality of this endogenous population in
protecting the host from disproportionate T cell activation
and autoreactive effector cells is underscored both in
experimental models and in humans in which the numbers
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and/or function of Treg are compromised [6,10,16–20]. In
mice, depletion of CD4+CD25+ T cells by neonatal (day 3)
thymectomy leads to spontaneous development of organ-
specific autoimmune diseases, including autoimmune
thyroiditis, gastritis, and wasting [19], which can be
reversed by adoptive transfer of Treg [21]. Treg are pivotal
in the protection of lymphopenic mice from induced
inflammatory bowel disease, experimental autoimmune
encephalomyelitis, diabetes, and allergy [16,18,22]. In
infectious models, Treg also influence the effector immune
response, as is evident in Leishmania major infection [20].
Both innate and adaptive immune responses are subject
to Treg control. Triggering of dendritic cells by Toll-like
receptor ligands expressed by invading pathogens leads
to the production of soluble factors, including IL-6, that
may render effector cells refractory to regulatory activity
[23]. Moreover, activated dendritic cells produce TGF-β,
which may further influence the development of Treg [24].
By such intersecting pathways, the innate and regulatory
arms of the immune system have the capacity to exert
sufficient control over each other to enable effector cells
to mount efficient immune responses with minimal
pathology. In human infectious, neoplastic, and auto-
immune diseases, Treg activities often mirror those in
murine systems. Numbers of Treg are reportedly reduced
in human autoimmune diseases [17,25], although their
significance in the evolution of immunopathogenesis
remains an area of continued exploration. Moreover,
increased CD4+CD25+ regulatory T cells have been
reported in HIV-1 immunodeficiency [26], and in lung
cancer patients the increased numbers of CD4+CD25+
regulatory T cells directly inhibit autologous T cell
proliferation [27]. Thus, this unique and persuasive
population of regulatory T cells has a crucial role in the
maintenance of tolerance and immune homeostasis
through immune suppression.
Mechanism of Treg suppression
Treg are both anergic, at least in vitro, and
immunosuppressive. The absence of Treg results in the
breakdown of tolerance and the development of
autoimmune diseases [28]. Our understanding of the
functional domain of these cells has rapidly advanced
through cell culture experiments. In vitro, the ability of
CD4+CD25+ Treg to suppress responder T cell
proliferation and cytokine production requires their
activation, is dependent on cell contact, and is antigen
nonspecific [1,6,10]. After years of searching for the
elusive mediator(s) of suppression consistent with the
accepted cell-contact-dependent mechanism, membrane-
associated TGF-β was identified as a pivotal perpetrator
[6,7,14]. In this regard, latent TGF-β was first reported to
be constitutively present on the surface of Treg [6,7];
subsequently, active TGF-β was identified [6,8,14]. In
vitro stimulation with anti-CD3 and antigen-presenting
cells (APCs) enhances membrane-bound active TGF-β,
which is consistent with the requirement that Treg
activation promotes their suppressive potential [6,13] (W
Chen, unpublished data). Blockade of cell-surface TGF-β
with neutralizing antibodies, with soluble TGF-β receptor,
or with recombinant latency-associated peptide disrupts
the ability of these cells to block responder T cell
proliferation, confirming TGF-β as an instrument of
suppression [6–8,12,13,15,29]. Still missing was the
connecting link by which membrane-bound TGF-β could
interact with the CD4+CD25– responder cells. Recently,
TGF-β receptor type II (TβRII) was detected at elevated
levels on responder T cells once they were activated
through their TCR, thereby providing the molecular bridge
by which TGF-β on the Treg orchestrates suppression of
the responder cells [6,8,12].
TGF-β β signaling and regulation
TGF-β is a potent cytokine and growth factor whose
biological activity is primarily regulated post-translationally
[30], because it is transcribed and translated as a small
latent complex composed not only of active TGF-β, but
also of a latency-associated peptide (LAP) to which it is
noncovalently bound and which prevents its interaction
with its specific receptors on the target cell surface. This
small latent complex can be associated with the latent
TGF-β1-binding protein, forming a large latent complex
thought to serve as a tether for binding proteins and matrix
molecules [31]. In this configuration, TGF-β is not active
but requires cleavage or dissociation from LAP to enable
its interaction with its cognate receptor complex, TβRII
Figure 1
Regulatory T cells mediate inflammatory and immune reactions.
CD4+CD25+ Treg can suppress CD4+CD25– T cell responses to
antigens through a contact-dependent, antigen-nonspecific
mechanism involving TGF-β. Treg suppress CD4+CD25– responder
T cell proliferation and cytokine production, reining in Th1 and/or Th2
immunity. Without adequate intercession by Treg, Th1- or
Th2-dominated responses may become pathogenic.64
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and TβRI [32]. Activation of TGF-β can occur by any of a
number of mechanisms including cleavage with plasmin
[33], interaction with αvβ6 [34], or through an ill-defined
interaction of LAP with thrombospondin I (TSP-I), a ligand
for the CD36 receptor [35]. Adding credence to a role for
TSP-1, the TSP-1-null mice exhibit persistent
inflammation, particularly in the pancreas and lung, and
display a phenotype with similarities to TGF-β-null mice
[36,37], although to a lesser extent because alternative
mechanisms of TGF-β activation compensate.
Nonetheless, TSP-1 is a major activator of TGF-β1 in vivo
[36], and a TSP peptide that activates TGF-β reverses the
TSP-1-null phenotype by dampening the tissue
inflammation. In a feedback loop, TGF-β augments TSP
secretion by dendritic cells and macrophages, and TGF-β-
treated APCs facilitate the generation of regulatory T cells
[38], creating an environment favorable for the induction
of suppression and/or tolerance to ensure the blunting of
any inflammatory reaction.
Often seeming paradoxical, activated TGF-β has both
stimulatory and inhibitory influences on T cell function
[6,8]. These apparently disparate effects are dependent
on context, including state of differentiation, presence of
other growth factors or cytokines, matrix molecules,
additional proximal cell populations, and membrane
receptor levels. Beyond its involvement in contact-
dependent suppression, soluble TGF-β can directly inhibit
T cell proliferation, suppress macrophage activation and
modulate dendritic cell function in its role as an
immunoregulatory cytokine. Deletion of this cytokine is
associated with lethal immune dysregulation and multi-
organ inflammatory disease [39,40].
In mediating its suppressive effects, TGF-β signals
through the type I and type II TGF-β serine–threonine
kinase receptors, TβRI and TβRII. Interaction of the TGF-β
ligand with these receptors on target cells engages a
signaling cascade precipitated by the phosphorylation of
cytosolic proteins identified as Smads [41,42]. When
CD4+CD25+ Treg are co-cultured with TCR-activated
CD4+CD25– responder T cells, there is a rapid
engagement of this intracellular signaling pathway that is
consistent with TGF-β as the link between these two cells
and the impending functional inhibition manifested in the
responder cell population [6,12,15]. In this regard,
phosphorylation of Smads, initially detected with
antibodies that recognize both Smad2 and Smad3 [6]
(W Chen, unpublished data), and more recently with
Smad2-specific antibodies [15], occurred within minutes
after exposure of responder T cells to Treg. Smad2 and
Smad3 serve as receptor-activated Smad signaling
intermediates, whereas Smad4 is a common Smad that
complexes with Smad2/3 to enable translocation to the
nucleus. Once within the nucleus, the Smad complex may
interact with specific DNA sequences and with multiple
specific transcription factors, in addition to transcriptional
coactivators and/or co-repressors, culminating in the
transcription of target genes and the transduction of a
variety of signals dependent on the target cell [41].
Smad2/3 are anchored to the plasma membrane through
the Smad anchor for receptor activation (SARA), which
probably increases the efficiency of activation by the TGF-
β-receptor complexes [43]. Smad2, rather than Smad3,
may be the critical connector in the intracellular signaling
pathway engaged in the responder cells by Treg surface-
bound TGF-β, because mice deficient in Smad3 respond
to Treg suppression and also to exogenous TGF-β [6] (W
Chen, unpublished data). In addition to that mediated by
Smad2, TGF-β signaling is regulated by complex
mechanisms in the cytoplasm and nucleus. Beyond
engaging Smad activity, TGF-β triggers the extracellular
signal-related kinase and p38 mitogen-activated kinase
pathways [44] to link additional signaling cascades
involved in modulating cell function.
Perturbations in this immunoregulatory circuit can occur
through dysregulation of the inhibitory Smad, Smad7,
which typically represses TGF-β signaling by interacting
with activated TGF-β receptors to prevent the activation of
Smad2/3 and/or by interfering with complex formation
between Smad2/3 and Smad4 [45]. Facilitating the
inhibitory Smad signals are the Smad ubiquitin regulatory
factors (Smurfs), E3 ubiquitin ligases, capable of inducing
polyubiquitination and degradation of TβRI [46,47].
Smad7 is inducible by TGF-β itself as part of a feedback
loop, as well as by the IFN-γ and NF-κB pathways [41].
Moreover, the transcriptional co-repressors c-Ski and
SnoN, by means of their interactions with Smad2/3/4,
repress TGF-β-induced transcription and are upregulated
by TGF-β as another negative feedback loop to maintain
control of this incredibly powerful molecule [41].
Dissection of these circuits will probably reveal pathways
by which suppression can be manipulated to orchestrate
changes in aberrant immunity.
Although the preponderance of evidence supports a major
role for TGF-β in the mediation of Treg suppressive activity,
there are likely to be additional factors and/or cofactors that
secondarily contribute to their function and that may
become prevalent in the absence of TGF-β and/or if TGF-β
is dysregulated. The identification and intersection points of
such pathways await further study. Among the factors that
contribute to the regulation of TGF-β in CD4+CD25+ Treg
are CD28, cytotoxic T lymphocyte  antigen-4,
glucocorticoid-induced TNF receptor and forkhead/winged
helix or forkhead box P3 encoded by Foxp3 [48–51].
Generation of Treg
Although Treg were originally considered to derive only
from thymic precursors [1], to be exported to the
periphery, and to represent less than 10% of CD4+ T cells65
[52], thereby limiting their potential for manipulation for
therapeutic considerations, important new evidence
documents that Treg can be expanded and/or induced de
novo from CD4+CD25– precursor T cells. How, where,
and if the size and function of this population can be
intentionally controlled is of the utmost importance. The
thymic derivation of Treg is genetically as well as
developmentally regulated, but it seems to be constitutive
and relatively stable. Recruitment to a site of autoimmune
reactivity may increase their numbers locally, but in a
limited fashion. The ability to coerce expansion of
functional Treg opens up possibilities for the manipulation
of inflammation and immunity. CD4+CD25+ Treg undergo
proliferation with TCR stimulation in the presence of high
doses of exogenous IL-2 (more than 100 U/ml) in vitro
[10]. Importantly, these expanded CD4+CD25+ regulatory
T cells preserve their anergic features and immuno-
suppressive ability once IL-2 is removed. This unique
aspect of CD4+CD25+ Treg has definite potential
application in designing future clinical therapy for auto-
immune diseases, inflammation and transplantation. None-
theless, the insufficiency of naturally derived CD4+CD25+
Treg in autoimmunity and other immune diseases has
driven the search for approaches to convert normal naive
CD4+CD25– T cells into CD4+CD25+ regulatory T cells.
The generation of functionally uncompromised
CD4+CD25+ Treg involves the unique induction of
forkhead/winged helix transcription factor Foxp3 (Scurfin)
in Foxp3-negative CD4+CD25– precursors. Foxp3 is
highly conserved, and in both mice and humans
genetically defective Foxp3 is associated with auto-
immune and inflammatory disease [48,53–57]. In Foxp3
null mice, the deficiency of CD4+CD25+ Treg results in a
lethal autoimmune syndrome [53,55,57]. In vitro, gene
transfer of Foxp3 converts naive CD4+CD25– T cells into
phenotypic and functional Treg [48,53,55,56], which is
consistent with the ability to rescue Foxp3-null mice with
adoptive transfer of Treg [55]. These data support the
pivotal and nonredundant role of this transcription factor in
Treg development and function. Conversely, the
overexpression of Foxp3 in a transgenic mouse model
results in enhanced numbers of CD4+CD25+ Treg and,
furthermore, Foxp3-expressing CD4+CD25–, as well as
CD4–CD8+, T cells in these transgenic mice constitutively
exhibit suppressive functions [57].
Despite the success of the artificial gene transfer of Foxp3
into CD4+CD25– naive T cells to coerce them into a
CD4+CD25+ regulatory T cell phenotype, the existence of
a physiologic inducer of Foxp3 was unknown. The recent
elucidation of a signaling pathway leading to the
conversion of CD4+CD25– precursors into Treg revealed
a pivotal role for TGF-β [8,12,14]. Moreover, the genetic
deletion of Foxp3 results in an overlapping phenotype with
the TGF-β1-null mice [40], implicating a connection
and/or shared mechanism of action. The induction of gene
expression of Foxp3, a transcription factor unique to Treg
[48,53–57] is, in fact, TGF-β dependent [12]. However,
TGF-β cannot act independently on precursor cells to
generate Treg but requires co-stimulation through TCR
and IL-2R [12,58]. Naive splenic CD4+CD25– T cells
cultured for 7 to 9 days with TCR stimulation and TGF-β in
the presence of APCs emerge as CD4+CD25+ Treg with
the ability to suppress CD4+ responder T cell proliferation.
A similar conversion pattern occurs in TCR transgenic
mice if the CD4+CD25– naive T cells are stimulated with
specific antigen and APCs with TGF-β added [12]. This
engagement of the TCR and co-stimulator molecules
(such as CD28) [49,50,59,60] in concert with TβRII
ligation triggers signaling pathways that culminate in
Foxp3 transcription, which is essential to generation of
Treg. In this fashion, TGF-β is not only expressed by Treg
but also programs their development and function.
TGF-β β-converted Treg control immune
responses in vivo
On the basis of this understanding of the novel
mechanism underlying conversion of CD4+CD25– T cells
into phenotypic and functional CD4+CD25+ Treg, the
expansion of Treg for therapeutic consideration becomes
an achievable goal. Provided that the regulatory conditions
are met, the converted CD4+CD25+ Treg function like
conventional Treg, at least in vitro. Although it has
previously been shown that naturally occurring
CD4+CD25+ Treg are potent inhibitors of innate/adaptive
immunity [61–63], induction of a population of Treg and
documentation of their in vivo potential was an important
next step. In pursuit of this goal, recent studies
demonstrated for the first time that the transfer of in vitro
generated Treg into disease models does in fact
ameliorate pathogenesis [12]. Initially, it was shown that
adoptive transfer of in vitro TGF-β-converted Treg
together with ovalbumin-specific TCR transgenic T cells
resulted in a profound inhibition of antigen-specific
expansion of naive CD4+ transgenic T cells in vivo.
Although the TGF-β-converted CD25+ suppressor
population (DO11.10 TCR transgenic, KJ1-26+)
proliferated  in vivo on immunization with ovalbumin
peptide, the recovered KJ1-26+ CD4+ T cells from
draining lymph nodes remained unresponsive to re-
challenge with ovalbumin peptide in vitro, produced no
antigen-specific IL-4 and IFN-γ, and expressed high levels
of CD25 [12], all consistent with professional
CD4+CD25+ regulatory T cells [64,65]. Moreover, in a
dramatic turnaround of allergen-induced asthmatic lung
disease, TGF-β-converted/induced Treg, when transferred
to an asthmatic mouse, suppressed allergen-induced
inflammation and pathogenesis [12]. In this model, mice
are immunized with house dust mite and then challenged
intratracheally with house dust mite to induce airway
hyperreactivity, mucus accumulation, eosinophilia and IgE
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production. Delivery of Treg to these asthmatic mice on
day 0 and 14 was able to prevent the immunopathogenic
response (Fig. 2), confirming the functional prowess of
these newly converted cells in the suppression of
inflammatory and immune responses in vivo.
Treg in autoimmune diseases
Human systemic lupus erythematosus (SLE) patients and
murine models of SLE manifest a wide range of
immunological abnormalities. The most pervasive of these
include the generation of pathogenic autoantibodies. In
this regard, 98% of human SLE patients possess
antinuclear antibodies and 50 to 80% of these have anti-
double-stranded DNA antibodies, the result of unchecked
B lymphocyte activation and antibody production,
probably due to uncontrolled T cell hyper-responsiveness.
Both Th1 and Th2 responses are elevated, as
demonstrated by the upregulation of proinflammatory
cytokines, notably IFN-γ, IL-6, IL-12, and IL-10, as well as
T cell-dependent autoantibody production. Interestingly,
these T and B lymphocyte abnormalities have been
attributed, at least partly, to defective production and
function of TGF-β [12,66]. In contrast to strong
suspicions, few data yet exist as to whether the
uncontrolled T and B cell activation and pathogenesis in
SLE can be attributed to a deficiency in CD4+CD25+
regulatory T cells. In this regard, one study indicated that
CD4+CD25+ T cells were significantly decreased in
patients with active SLE in comparison with normal
subjects and patients with an inactive stage of the disease
[67], and in another recent study [68] Treg were reported
to be abnormal in number, phenotype, and function in
patients with active SLE. However, the exact role of the
decreased CD4+CD25+ Treg levels in the pathogenesis
of SLE awaits demonstration of a significant correlation
between the levels of CD4+CD25+ Treg and inactive
disease or flare activity [69].
In rheumatoid arthritis (RA), the relationship between
CD4+CD25+ Treg and Th1-dependent pathogenesis of
the disease also remains under study. It was recently
suggested [70] that no significant difference in
suppressive activity was found between CD4+CD25+
T cells from peripheral blood of RA patients and healthy
control subjects, although the numbers may be less [25].
Nonetheless, CD4+CD25+ T cells from synovial fluid
reportedly had a significantly higher suppressive activity
than those in peripheral blood of RA patients. Notably,
despite the presence of these highly functional Treg in
synovial fluid, there was still ongoing inflammation in the
joints, indicating the complex picture of RA pathogenesis,
which might reflect a prominent imbalance between
regulatory  and inflammatory checkpoints. In an
encouraging experimental therapy study, patients with RA
who were treated for 6 months with oral dnaJP1, a peptide
that induces proinflammatory T cell responses in naive
RA patients, manifested increased Foxp3+CD4+CD25+
T cells, suggesting that the treatment induced the
emergence (enhancement) of T cells with the regulatory
phenotype [71]. In short, despite the complex picture of
Treg in autoimmunity, it can be envisioned that it will
become feasible to manipulate regulatory T cells for
therapeutic benefit. With continued efforts, a better
understanding and more advanced techniques will emerge
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Figure 2
Treg expanded in vitro suppress allergen-induced asthma in vivo. Mice sensitized to house dust mite (HDM) by intraperitoneal (ip) injection with
HDM on days 0 and 7 and then challenged by intratracheal (it) injection on days 14 and 21 were injected intraperitoneally on days 0 and 14 with
Treg. Three days after the second intratracheal challenge with HDM, the lungs were assessed for histopathology by periodic acid Schiff staining for
mucopolysaccharides (red). Inflammatory pathology and mucin obstruction of the airways were strikingly reduced in mice receiving Treg [12].67
for the induction and/or expansion of Treg to enhance
their role in autoimmunity, allergy, and graft rejection.
Conclusion
Innate and adaptive immune responses are essential to
protect the host from a plethora of potentially pathogenic
microorganisms, but countermeasures to prevent reactivity
of self are equally essential. Although protection against
self-recognition-induced autoimmunity is accomplished in
large part by the central deletion of autoreactive T cells
during intrathymic development, this process is not
perfect and self-reactive escapees can wreak havoc on
the immune system. However, among the backup
pathways in the periphery to protect us from self-
destruction are deletion, anergy, ignorance, and active
suppression. Among these, current interest has zeroed in
on CD4+CD25+ regulatory T cells, which can profoundly
suppress responder T cell proliferation and cytokines in
vitro and  in vivo. Originally considered an exclusive
product of the thymus, important new data indicate that
these cells can be generated from peripheral CD4+ T cells
and expanded for delivery as a cellular therapeutic
strategy. Opportunities to use suppressor T cell
populations in the treatment of debilitating autoimmune
diseases, allergy, chronic infectious diseases, and
transplant rejection are no longer a dream of the future but
are an emerging reality. Moreover, as we illuminate the
mechanisms of regulation of these Treg, it might also
become feasible to diminish, rather than augment, their
numbers/activity to promote tumor rejection and vaccine
responses and/or to reverse immunodeficiency diseases.
Competing interests
The author(s) declare that they have no competing interests.
References
1. Sakaguchi S: Regulatory T cells: key controllers of immuno-
logic self-tolerance. Cell 2000, 101:455-458.
2. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH:
Identification and functional characterization of human
CD4+CD25+ T cells with regulatory properties isolated from
peripheral blood. J Exp Med 2001, 193:1285-1294.
3. Levings MK, Sangregorio R, Roncarolo MG: Human CD25+CD4+
T regulatory cells suppress naive and memory T cell prolifera-
tion and can be expanded in vitro without loss of function. J
Exp Med 2001, 193:1295-1302.
4. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G: Ex
vivo isolation and characterization of CD4+CD25+ T cells with
regulatory properties from human blood. J Exp Med 2001,
193:1303-1310.
5. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN:
Human anergic/suppressive CD4+CD25+ T cells: a highly dif-
ferentiated and apoptosis-prone population. Eur J Immunol
2001, 31:1122-1131.
6. Chen W, Wahl SM: TGF-β β: the missing link in CD4+CD25+ reg-
ulatory T cell-mediated immunosuppression. Cytokine Growth
Factor Rev 2003, 14:85-89.
7. Nakamura K, Kitani A, Strober W: Cell contact-dependent
immunosuppression by CD4+CD25+ regulatory T cells is
mediated by cell surface-bound transforming growth factor
beta. J Exp Med 2001, 194:629-644.
8. Wahl SM, Chen W: TGF-β β: how tolerant can it be? Immunol Res
2003, 28:167-179.
9. Oida T, Zhang X, Goto M, Hachimura S, Totsuka M, Kaminogawa
S, Weiner HL: CD4+CD25– T cells that express latency-asso-
ciated peptide on the surface suppress CD4+CD45RBhigh-
induced colitis by a TGF-beta-dependent mechanism. J
Immunol 2003, 170:2516-2522.
10. Shevach EM: CD4+ CD25+ suppressor T cells: more ques-
tions than answers. Nat Rev Immunol 2002, 2:389-400.
11. Piccirillo CA, Letterio JJ, Thornton AM, McHugh RS, Mamura M,
Mizuhara H, Shevach EM: CD4+CD25+ regulatory T cells can
mediate suppressor function in the absence of transforming
growth factor beta1 production and responsiveness. J Exp
Med 2002, 196:237-246.
12. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G,
Wahl SM: Conversion of peripheral CD4+CD25– naive T cells
to CD4+CD25+ regulatory T cells by TGF-beta induction of
transcription factor Foxp3. J Exp Med 2003, 198:1875-1886.
13. Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V,
Romagnani P, Maggi E, Romagnani S: Phenotype, localization,
and mechanism of suppression of CD4+CD25+ human thymo-
cytes. J Exp Med 2002, 196:379-387.
14. Wahl SM, Swisher J, McCartney-Francis N, Chen W: TGF-beta:
the perpetrator of immune suppression by regulatory T cells
and suicidal T cells. J Leukoc Biol 2004, 76:15-24.
15. Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H,
Strober W: TGF-beta1 plays an important role in the mecha-
nism of CD4+CD25+ regulatory T cell activity in both humans
and mice. J Immunol 2004, 172:834-842.
16. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Bandeira A:
On the ontogeny and physiology of regulatory T cells. Immunol
Rev 2001, 182:5-17.
17. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA: Loss of func-
tional suppression by CD4+CD25+ regulatory T cells in
patients with multiple sclerosis. J Exp Med 2004, 199:971-979.
18. Furtado GC, Olivares-Villagomez D, Curotto de Lafaille MA,
Wensky AK, Latkowski JA, Lafaille JJ: Regulatory T cells in spon-
taneous autoimmune encephalomyelitis. Immunol Rev 2001,
182:122-134.
19. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T,
Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T: Immuno-
logic tolerance maintained by CD25+ CD4+ regulatory T cells:
their common role in controlling autoimmunity, tumor immu-
nity, and transplantation tolerance. Immunol Rev 2001, 182:18-
32.
20. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL:
CD4+CD25+ regulatory T cells control Leishmania major per-
sistence and immunity. Nature 2002, 420:502-507.
21. Asano M, Toda M, Sakaguchi N, Sakaguchi S: Autoimmune
disease as a consequence of developmental abnormality of a
T cell subpopulation. J Exp Med 1996, 184:387-396.
22. Shevach EM, McHugh RS, Piccirillo CA, Thornton AM: Control of
T-cell activation by CD4+ CD25+ suppressor T cells. Immunol
Rev 2001, 182:58-67.
23. Pasare C, Medzhitov R: Toll pathway-dependent blockade of
CD4+CD25+ T cell-mediated suppression by dendritic cells.
Science 2003, 299:1033-1036.
24. Verhasselt V, Vosters O, Beuneu C, Nicaise C, Stordeur P,
Goldman M: Induction of FOXP3-expressing regulatory
CD4pos T cells by human mature autologous dendritic cells.
Eur J Immunol 2004, 34:762-772.
25. Bluestone JA, Abbas AK: Natural versus adaptive regulatory T
cells. Nat Rev Immunol 2003, 3:253-257.
26. Kinter AL, Hennessey M, Bell A, Kern S, Lin Y, Daucher M, Planta
M, McGlaughlin M, Jackson R, Ziegler SF, Fauci AS:
CD25(+)CD4(+) regulatory T cells from the peripheral blood
of asymptomatic HIV-infected individuals regulate CD4(+)
and CD8(+) HIV-specific T cell immune responses in vitro and
are associated with favorable clinical markers of disease
status. J Exp Med 2004, 200:331-343.
27. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL,
Kaiser LR, June CH: Cutting edge: regulatory T cells from lung
cancer patients directly inhibit autologous T cell proliferation.
J Immunol 2002, 168:4272-4276.
28. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immuno-
logic self-tolerance maintained by activated T cells express-
ing IL-2 receptor alpha-chains (CD25). Breakdown of a single
mechanism of self-tolerance causes various autoimmune dis-
eases. J Immunol 1995, 155:1151-1164.
Available online http://arthritis-research.com/content/7/2/6268
29. Zhang X, Izikson L, Liu L, Weiner HL: Activation of CD25+CD4+
regulatory T cells by oral antigen administration. J Immunol
2001, 167:4245-4253.
30. Khalil N: TGF-beta: from latent to active. Microbes Infect 1999,
1:1255-1263.
31. Oklu R, Hesketh R: The latent transforming growth factor β β
binding protein (LTBP) family. Biochem J 2000, 352:601-610.
32. Shi Y, Massagué J: Mechanisms of TGF-β β signaling from cell
membrane to the nucleus. Cell 2003, 113:685-700.
33. Annes JP, Munger JS, Rifkin DB: Making sense of latent TGFβ β
activation. J Cell Sci 2003, 116:217-224.
34. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J,
Pittet JF, Kaminski N, Garat C, Matthay MA, et al.: The integrin α αvβ β6
binds and activates latent TGFβ β1: a mechanism for regulating
pulmonary inflammation and fibrosis. Cell 1999, 96:319-328.
35. Murphy-Ullrich JE, Poczatek M: Activation of latent TGF-beta by
thrombospondin-1: mechanisms and physiology. Cytokine
Growth Factor Rev 2000, 11:59-69.
36. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler
J, Hynes RO, Boivin GP, Bouck N: Thrombospondin-1 is a
major activator of TGF-β β1 in vivo. Cell 1998, 93:1159-1170.
37. Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn
H, Hynes RO: Thrombospondin-1 is required for normal
murine pulmonary homeostasis and its absence causes
pneumonia. J Clin Invest 1998, 101:982-992.
38. Masli S, Turpie B, Hecker KH, Streilein JW: Expression of
thrombospondin in TGFbeta-treated APCs and its relevance
to their immune deviation-promoting properties. J Immunol
2002, 168:2264-2273.
39. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC,
Roberts AB, Sporn MB, Ward JM, Karlsson S: Transforming
growth factor β β1 null mutation in mice causes excessive
inflammatory response and early death. Proc Natl Acad Sci
USA 1993, 90:770-774.
40. Christ M, McCartney-Francis NL, Kulkarni AB, Ward JM, Mizel DE,
Mackall CL, Gress RE, Hines KL, Tian H, Karlsson S, et al.:
Immune dysregulation in TGF-beta 1-deficient mice. J
Immunol 1994, 153:1936-1946.
41. Miyazono K, ten Dijke P, Heldin CH: TGF-beta signaling by
Smad proteins. Adv Immunol 2000, 75:115-157.
42. Roberts AB: TGF-beta signaling from receptors to the nucleus.
Microbes Infect 1999, 1:1265-1273.
43. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL: SARA,
a FYVE domain protein that recruits Smad2 to the TGFβ β
receptor. Cell 1998, 95:779-791.
44. Takekawa M, Tatebayashi K, Itoh F, Adachi M, Imai K, Saito H:
Smad-dependent GADD45β β expression mediates delayed
activation of p38 MAP kinase by TGF-β β. EMBO J 2002, 21:
6473-6482.
45. Suzuki C, Murakami G, Fukuchi M, Shimanuki T, Shikauchi Y,
Imamura T, Miyazono K: Smurf1 regulates the inhibitory activity
of Smad7 by targeting Smad7 to the plasma membrane. J
Biol Chem 2002, 277:39919-39925.
46. Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura
T, Miyazono K: Smurf1 interacts with transforming growth
factor-β β type I receptor through Smad7 and induces receptor
degradation. J Biol Chem 2001, 276:12477-12480.
47. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H,
Thomsen GH, Wrana JL: Smad7 binds to Smurf2 to form an E3
ubiquitin ligase that targets the TGF β β receptor for degrada-
tion. Mol Cell 2000, 6:1365-1375.
48. Schubert LA, Jeffery E, Zhang Y, Ramsdell F, Ziegler SF: Scurfin
(FOXP3) acts as a repressor of transcription and regulates T
cell activation. J Biol Chem 2001, 276:37672-37679.
49. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe
A, Bluestone JA: B7/CD28 costimulation is essential for the
homeostasis of the CD4+CD25+ immunoregulatory T cells
that control autoimmune diabetes. Immunity 2000, 12:431-440.
50. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi
N, Mak TW, Sakaguchi S: Immunologic self-tolerance main-
tained by CD25+CD4+ regulatory T cells constitutively
expressing cytotoxic T lymphocyte-associated antigen 4. J
Exp Med 2000, 192:303-310.
51. Read S, Malmstrom V, Powrie F: Cytotoxic T lymphocyte-asso-
ciated antigen 4 plays an essential role in the function of
CD25+CD4+ regulatory cells that control intestinal inflamma-
tion. J Exp Med 2000, 192:295-302.
52. Apostolou I, Sarukhan A, Klein L, von Boehmer H: Origin of regu-
latory T cells with known specificity for antigen. Nat Immunol
2002, 3:756-763.
53. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB,
Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F: Dis-
ruption of a new forkhead/winged-helix protein, scurfin,
results in the fatal lymphoproliferative disorder of the scurfy
mouse. Nat Genet 2001, 27:68-73.
54. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N,
Levy-Lahad E, Mazzella M, Goulet O, Perroni L, et al.: X-linked
neonatal diabetes mellitus, enteropathy and endocrinopathy
syndrome is the human equivalent of mouse scurfy. Nat
Genet 2001, 27:18-20.
55. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the
development and function of CD4+CD25+ regulatory T cells.
Nat Immunol 2003, 4:330-336.
56. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell
development by the transcription factor Foxp3. Science 2003,
299:1057-1061.
57. Khattri R, Cox T, Yasayko SA, Ramsdell F: An essential role for
Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003, 4:
337-342.
58. Horwitz DA, Zheng SG, Gray JD: The role of the combination of
IL-2 and TGF-beta or IL-10 in the generation and function of
CD4+ CD25+ and CD8+ regulatory T cell subsets. J Leukoc
Biol 2003, 74:471-478.
59. Liu Z, Geboes K, Hellings P, Maerten P, Heremans H, Vanden-
berghe P, Boon L, van Kooten P, Rutgeerts P, Ceuppens JL: B7
interactions with CD28 and CTLA-4 control tolerance or induc-
tion of mucosal inflammation in chronic experimental colitis. J
Immunol 2001, 167:1830-1838.
60. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M,
Shimizu J, Sakaguchi S: Immunologic self-tolerance main-
tained by CD25+CD4+ naturally anergic and suppressive T
cells: induction of autoimmune disease by breaking their
anergic/suppressive state. Int Immunol 1998, 10:1969-1980.
61. Maloy KJ, Salaun L, Cahill R, Dougan G, Saunders NJ, Powrie F:
CD4+CD25+ TR cells suppress innate immune pathology
through cytokine-dependent mechanisms. J Exp Med 2003,
197:111-119.
62. Grundstrom S, Cederbom L, Sundstedt A, Scheipers P, Ivars F:
Superantigen-induced regulatory T cells display different sup-
pressive functions in the presence or absence of natural
CD4+CD25+ regulatory T cells in vivo. J Immunol 2003, 170:
5008-5017.
63. Montagnoli C, Bacci A, Bozza S, Gaziano R, Mosci P, Sharpe AH,
Romani L: B7/CD28-dependent CD4+CD25+ regulatory T
cells are essential components of the memory-protective
immunity to Candida albicans. J Immunol 2002,  169:6298-
6308.
64. Walker LS, Chodos A, Eggena M, Dooms H, Abbas AK: Antigen-
dependent proliferation of CD4+ CD25+ regulatory T cells in
vivo. J Exp Med 2003, 198:249-258.
65. Klein L, Khazaie K, von Boehmer H: In vivo dynamics of antigen-
specific regulatory T cells not predicted from behavior in vitro.
Proc Natl Acad Sci USA 2003, 100:8886-8891.
66. Chen W, Wahl SM: TGF-beta: receptors, signaling pathways
and autoimmunity. Curr Dir Autoimmun 2002, 5:62-91.
67. Crispin JC, Martinez A, Alcocer-Varela J: Quantification of regu-
latory T cells in patients with systemic lupus erythematosus. J
Autoimmun 2003, 21:273-276.
68. Valencia X, Olson D, He LS, Illei G, Lipsky P: CD4+CD25+ T reg-
ulatory cells in autoimmune diseases. Arthritis Rheum 2003,
48 Suppl. S:411.
69. Liu MF, Wang CR, Fung LL, Wu CR: Decreased CD4+CD25+ T
cells in peripheral blood of patients with systemic lupus ery-
thematosus. Scand J Immunol 2004, 59:198-202.
70. van Amelsfort J, Jacobs K, Bijlsma JWJ, Taams L, Lafeber F:
CD4+CD25+ regulatory T cells in rheumatoid arthritis: differ-
ences in presence, phenotype and function between periph-
eral blood and synovial fluid. Arthritis Rheum 2003, 48 Suppl.
S:1159.
71. Prakken BJ, Samodal R, Le TD, Giannoni F, Yung GP, Scavulli J,
Amox D, Roord S, de Kleer I, Bonnin D, et al.: Epitope-specific
immunotherapy induces immune deviation of proinflamma-
tory T cells in rheumatoid arthritis. Proc Natl Acad Sci USA
2004, 101:4228-4233.
Arthritis Research & Therapy    Vol 7 No 2 Wahl and Chen